TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00831532
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimebon 5mg in moderate hepatic impairment patients
Study: NCT00831532
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimebon 5mg in Severe Hepatic Impairment
Study: NCT01398111
Drug: Glycopyrrolate + Formoterol
Normalized name: FORMOTEROL/GLYCOPYRROLATE
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: glycopyrrolate pMDI + formoterol pMDI
Study: NCT01398111
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycopyrrolate pMDI
Study: NCT01398111
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: formoterol pMDI
Study: NCT03808168
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
Study: NCT03639766
Drug: AbobotulinumtoxinA
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
Study: NCT02165046
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02165046
Drug: Procaterol
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01380184
Drug: ridaforolimus
Normalized name: Ridaforolimus
DrugBank: Ridaforolimus (DB06233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
Study: NCT01998451
Drug: Tauroursodeoxycholic acid
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
Study: NCT00834912
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
Study: NCT00834912
Drug: Tramadol HCl
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
Study: NCT00834912
Drug: Tramadol HCl
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
Study: NCT03425929
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration, 24 international units (IU) oxytocin.
Study: NCT01461772
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
Study: NCT01461772
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
Study: NCT00044343
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00885599
Drug: Listerine Antiseptic Mouth Rinse
Normalized name: Listerine Antiseptic
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study: NCT02188615
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: only Radical Chemoradiotherapy
Study: NCT01228630
Drug: Allegra-D
Normalized name: Allegra-D
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
Study: NCT00344773
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg tablet oral tablet once daily
Study: NCT00040885
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00684853
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg of bevacizumab intravitreal
Study: NCT00684853
Drug: vetaporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: full fluence of vetaporfin
Study: NCT02419118
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment of myeloma patients with Daratumumab
Study: NCT02419118
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment of myeloma patients
Study: NCT02419118
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment of myeloma patients
Study: NCT02766244
Drug: Antibiotic Ointment
Normalized name: CVS Antibiotic Ointment
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic ointment
Study: NCT02357147
Drug: Amatuximab
Normalized name: Amatuximab
DrugBank: Amatuximab (DB12845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression.
Study: NCT02357147
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combination Phase - Pemetrexed 500 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
Study: NCT02357147
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination Phase - Cisplatin 75 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
Study: NCT02925546
Drug: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)
Normalized name: API
DrugBank: GSK2798745 (DB16033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
Study: NCT02925546
Drug: GSK2798745 Micronized API with SLS and hypermellose (Tablet B)
Normalized name: API
DrugBank: GSK2798745 (DB16033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
Study: NCT02925546
Drug: GSK2798745 milled API without SLS and hypermellose (Tablet C)
Normalized name: API
DrugBank: GSK2798745 (DB16033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
Study: NCT04268420
Drug: ALFQ
Normalized name: ALFQ component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
Study: NCT00256698
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intramuscular injection 250 mg loading dose (LD) regimen
Study: NCT00256698
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg oral tablet
Study: NCT00368264
Drug: infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
Study: NCT00003055
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003055
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01748253
Drug: Telmisartan-amlodipine tablet administration group (morning)
Normalized name: telmisartan, amlodipine and hydrochlorothiazide
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
Study: NCT01748253
Drug: Telmisartan-amlodipine tablet administration group (bedtime)
Normalized name: telmisartan, amlodipine and hydrochlorothiazide
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
Study: NCT00323154
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02064907
Drug: Dexlansoprazole Delayed Release Orally Disintegrating Tablets
Normalized name: dexlansoprazole Delayed Release Oral Capsule
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
Study: NCT02064907
Drug: Dexlansoprazole Delayed Release Capsules
Normalized name: dexlansoprazole Delayed Release Oral Capsule
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole delayed-release capsules
Study: NCT01234545
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
Study: NCT02409836
Drug: Marketed Dentifrice
Normalized name: acetaminophen
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed Dentifrice
Study: NCT02409836
Drug: Marketed Flavored Dentifrice
Normalized name: blackberry flavor
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hawaiian Punch Flavored
Study: NCT02409836
Drug: Marketed Flavored Dentifrice
Normalized name: blackberry flavor
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bubble Gum Flavored
Study: NCT03941535
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
Study: NCT01520116
Drug: Stage 1 - ATS907 - Dose 1
Normalized name: mugwort sage pollen extract 1 MG/ML
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD and/or BID dosing for 28 days
Study: NCT01520116
Drug: Stage 1 - ATS907 - Dose 2
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD and/or BID dosing for 28 days
Study: NCT01520116
Drug: Stage 1 - ATS907 - Dose 3
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QD and/or BID dosing for 28 days
Study: NCT01520116
Drug: Stage 1 - ATS907 - Dose 4
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD and/or BID dosing for 28 days
Study: NCT01520116
Drug: Stage 1 - Vehicle
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD and/or BID dosing for 28 days
Study: NCT01520116
Drug: Stage 2 - ATS907 - Dose A - to be selected based on Stage 1
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD and/or BID dosing for 4 days
Study: NCT01520116
Drug: Stage 2 - ATS907 - Dose B - to be selected based on Stage 1
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: QD and/or BID dosing for 4 days
Study: NCT01520116
Drug: Timoptic
Normalized name: Timoptic
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5%
Study: NCT00275210
Drug: Oxaliplatin (SR96669)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00066066
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
Study: NCT00066066
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
Study: NCT02753062
Drug: bendamustine, rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
Study: NCT02268409
Drug: luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: subcutaneous injection
Study: NCT02155738
Drug: IV normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV normal saline
Study: NCT04638465
Drug: Cisplatin - Dose Level 1
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 Cycles of 40 mg/m2
Study: NCT04638465
Drug: Cisplatin - Dose Level 2
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 Cycles of 40 mg/m2
Study: NCT00234195
Drug: bupropion extended release (Wellbutrin XL)
Normalized name: bupropion Extended Release Oral Tablet
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00238277
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04918563
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
Study: NCT04976842
Drug: OBA
Normalized name: Moban
DrugBank: Molindone (DB01618)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
Study: NCT03873987
Drug: Current Formulation of Oritavancin
DrugBank: Oritavancin (DB04911)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
Study: NCT03873987
Drug: Kimyrsa
Normalized name: Kimyrsa
DrugBank: Oritavancin (DB04911)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
Study: NCT00426283
Drug: Flovent
Normalized name: Flovent
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1760 mcg daily
Study: NCT03573986
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
Study: NCT02620904
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006240
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006240
Drug: oral sodium phenylbutyrate
Normalized name: Sodium Phenylbutyrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03674060
Drug: Nexavar tab
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nexavar 200mg/tablet, PO, 1 tablet
Study: NCT00563147
Drug: tivozanib (AV-951) plus temsirolimus
Normalized name: Temsirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
Study: NCT00006294
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participant's drug dose will be titrated from 10mg to 40mg over the course of the study
Study: NCT00006294
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participant's drug dose will be titrated from 10mg to 40mg over the course of the study
Study: NCT00006294
Drug: Doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participant's drug dose will be titrated from 2mg to 8mg over the course of the study
Study: NCT01217060
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
Study: NCT01217060
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
Study: NCT01217060
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg IV 30 minutes prior to weekly Docetaxel.
Study: NCT00004888
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02082210
Drug: Emibetuzumab
Normalized name: Emibetuzumab
DrugBank: Emibetuzumab (DB11849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Intravenously (IV)
Study: NCT02082210
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered Intravenously (IV)
Study: NCT02397330
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02397330
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00621881
Drug: naproxcinod
Normalized name: Naproxcinod
DrugBank: Naproxcinod (DB06682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg bid
Study: NCT02174848
Drug: Deferiprone oral solution
Normalized name: deferiprone Oral Solution
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
Study: NCT00705978
Drug: Pancreatin
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
Study: NCT00254566
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 X 400mg capsule once daily for 5 days
Study: NCT02094716
Drug: Permethrin Foam 4%
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application, whole-body treatment
Study: NCT02094716
Drug: Permethrin Foam 5%
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application, whole-body treatment
Study: NCT02094716
Drug: Vehicle Foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application, whole-body treatment
Study: NCT00902564
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible-dosed (5 to 20 mg Oral Tablets Daily)
Study: NCT00116831
Drug: Glipizide
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral anti-diabetic medication
Study: NCT00116831
Drug: rosiglitazone maleate
Normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral antidiabetic medication
Study: NCT03616912
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT02130063
Drug: iron isomaltoside 1000 (Monofer®)
Normalized name: ferric carboxymaltose
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02130063
Drug: iron sucrose (Venofer®)
Normalized name: iron sucrose Injection [Venofer]
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02418468
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 150µg capsules for inhalation daily
Study: NCT01232296
Drug: dovitinib
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg p.o. o.d. 5 days on/2 days off
Study: NCT01232296
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg p.o. b.i.d.